Guy J. Clarkson

A Potent Trans‐Diimine Platinum Anticancer Complex Photoactivated by Visible Light

Activating platinum with light: An inert platinum(IV) diazido complex trans, trans,trans-[Pt(N3)2(OH)2(py)2] becomes potently cytotoxic to cancer cells when activated by low doses of visible light.

Ru(II) complexes of N-Alkylated TsDPEN ligands in asymmetric transfer hydrogenation of ketones and imines

N-Alkylated TsDPEN derivatives bearing a small alkyl group act as highly efficient ligands in Ru(II) complexes for the asymmetric transfer hydrogenation of imines and ketones. A larger alkyl group serves to significantly reduce the activity of the catalyst; however, high enantiomeric excesses are still obtained. An X-ray crystal structure of the N-benzyl derivative reveals a conformation that permits hydrogen transfer through a six-membered transition state. A transition state structure for the imine reduction process is proposed.

The Potent Oxidant Anticancer Activity of Organoiridium Catalysts

Platinum complexes are the most widely used anticancer drugs; however, new generations of agents are needed. The organoiridium(III) complex [(η5-Cpxbiph)Ir(phpy)(Cl)] (1-Cl), which contains π-bonded biphenyltetramethylcyclopentadienyl (Cpxbiph) and C∧N-chelated phenylpyridine (phpy) ligands, undergoes rapid hydrolysis of the chlorido ligand. In contrast, the pyridine complex [(η5-Cpxbiph)Ir(phpy)(py)]+ (1-py) aquates slowly, and is more potent (in nanomolar amounts) than both 1-Cl and cisplatin towards a wide range of cancer cells. The pyridine ligand protects 1-py from rapid reaction with intracellular glutathione. The high potency of 1-py correlates with its ability to increase substantially the level of reactive oxygen species (ROS) in cancer cells. The unprecedented ability of these iridium complexes to generate H2O2 by catalytic hydride transfer from the coenzyme NADH to oxygen is demonstrated. Such organoiridium complexes are promising as a new generation of anticancer drugs for effective oxidant therapy.

Catalytic alkene cyclohydroamination via an imido mechanism

Chiral-at-metal half-sandwich diamide complexes catalyse enantioselective cyclohydroamination of aminoalkenes at unexpectedly high rates given their high coordination number and steric bulk; substantial evidence is presented which argues against the established sigma-bond insertion process and is strongly indicative of an imido [2+2] cycloaddition mechanism.

Organometallic osmium arene complexes with potent cancer cell cytotoxicity

Iodido osmium(II) complexes [Os(η(6)-arene)(XY)I](+) (XY = p-hydroxy or p-dimethylaminophenylazopyridine, arene = p-cymene or biphenyl) are potently cytotoxic at nanomolar concentrations toward a panel of human cancer cell lines; e.g., IC(50) = 140 nM for [Os(η(6)-bip)(azpy-NMe(2))I](+) toward A2780 ovarian cancer cells. They exhibit low toxicity and negligible deleterious effects in a colon cancer xenograft model, giving rise to the possibility of a broad therapeutic window. The most active complexes are stable and inert toward aquation. Their cytotoxic activity appears to involve redox mechanisms.

Amide Linkage Isomerism As an Activity Switch for Organometallic Osmium and Ruthenium Anticancer Complexes

We show that the binding mode adopted by picolinamide derivatives in organometallic Os(II) and Ru(II) half-sandwich complexes can lead to contrasting cancer cell cytotoxicity. N-Phenyl picolinamide derivatives (XY) in Os(II) (1, 3-5, 7, 9) and Ru(II) (2, 6, 8, 10) complexes [(eta(6)-arene)(Os/Ru)(XY)Cl](n+), where arene = p-cymene (1-8, 10) or biphenyl (9), can act as N,N- or N,O-donors. Electron-withdrawing substituents on the phenyl ring resulted in N,N-coordination and electron-donating substituents in N,O-coordination. Dynamic interconversion between N,O and N,N configurations can occur in solution and is time- and temperature- (irreversible) as well as pH-dependent (reversible). The neutral N,N-coordinated compounds (1-5 and 9) hydrolyzed rapidly (t(1/2) <or= min), exhibited significant (32-70%) and rapid binding to guanine, but no binding to adenine. The N,N-coordinated compounds 1, 3, 4, and 9 exhibited significant activity against colon, ovarian, and cisplatin-resistant ovarian human cancer cell lines (3 >> 4 > 1 > 9). In contrast, N,O-coordinated complexes 7 and 8 hydrolyzed slowly, did not bind to guanine or adenine, and were nontoxic.

A delicate balance between sp2 and sp3 C-H bond activation: a Pt(II) complex with a dual agostic interaction.

2-tert-Butyl-6-(4-fluorophenyl)pyridine reacts with K(2)PtCl(4) via the activation of an sp(2) C-H bond to give a cyclometalated complex that contains a bifurcated agostic interaction. Rearrangement of this complex results in the activation of an sp(3) C-H bond, and reaction eventually leads to a doubly cyclometalated complex where both sp(2) and sp(3) C-H bonds have been activated. Deuterium exchange studies show that a delicate balance exists between the two cyclometalations.

Self-assembling optically pure Fe(A-B)3 chelates.

Optically pure, single diastereomer fac-tris(diimine) complexes of Fe(II) are available from a remarkably facile one-pot procedure using a range of readily available (R)-2-phenylglycinol derivatives.

Mechanism of Catalytic Cyclohydroamination by Zirconium Salicyloxazoline Complexes

The mechanism of hydroamination/cyclization of primary aminoalkenes by catalysts based on Cp*LZr(NMe(2))(2) (L = κ(2)-salicyloxazoline) is investigated in a range of kinetic, stoichiometric, and structural studies. The rate law is found to be d[substrate]/dt = k[catalyst](1)[substrate](0) for all catalysts and aminoalkenes studied. The overall rate is similar for formation of five- and six-membered rings, and a substantial KIE (k(H)/k(D)) is observed, indicating the involvement of N-H bond-breaking in a rate-determining step (RDS) which is not ring-closure. Remarkably, the reaction proceeds at the same rate in THF as it does in toluene, but added non-cyclizable amine slows the reaction, indicating that while the metal is not acting as a Lewis acid in the RDS, the activated substrate is involved. Also in contrast to other catalysts, increasing steric bulk improves the rate, and the origins of this are investigated by X-ray crystallography. Thermodynamic parameters extracted from eight independent kinetic studies indicate moderate ordering (ΔS(double dagger) = -13 to -23 cal/K·mol) and substantial overall bond disruption (ΔH(double dagger) = 17 to 21 kcal/mol) in the rate-determining transition state. Secondary amines are unreactive, as is a catalyst with a single aminolyzable site, thus excluding an amido mechanism. A catalytic cycle involving rate-determining formation of a reactive imido species is proposed. Stoichiometric steps in the process are shown to be feasible and have appropriate rates by synthetic and in situ NMR spectroscopic studies. The fate of the catalyst in the absence of excess amine (at the end of the catalytic reaction) is conversion to a metallacyclic species arising from CH activation of a peripheral substituent.

Contrasting anticancer activity of half-sandwich iridium(III) complexes bearing functionally diverse 2-phenylpyridine ligands

We report the synthesis, characterization, and antiproliferative activity of 15 iridium(III) half-sandwich complexes of the type [(η5-Cp*)Ir(2-(R′-phenyl)-R-pyridine)Cl] bearing either an electron-donating (−OH, −CH2OH, −CH3) or electron-withdrawing (−F, −CHO, −NO2) group at various positions on the 2-phenylpyridine (2-PhPy) chelating ligand giving rise to six sets of structural isomers. The X-ray crystal structures of [(η5-Cp*)Ir(2-(2′-fluorophenyl)pyridine)Cl] (1) and [(η5-Cp*)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) exhibit the expected “piano-stool” configuration. DFT calculations showed that substituents caused only localized effects on the electrostatic potential surface of the chelating 2-PhPy ligand of the complexes. Hydrolysis of all complexes is rapid, but readily reversed by addition of NaCl. The complexes show preferential binding to 9-ethylguanine over 9-methyladenine and are active catalysts for the oxidation of NADH to NAD+. Antiproliferative activity experiments in A2780 ovarian, MCF-7 breast, A549 lung, and HCT116 colon cancer cell lines showed IC50 values ranging from 1 to 89 μM, with the most potent complex, [(η5-Cp*)Ir(2-(2′-methylphenyl)pyridine)Cl] (13) (A2780 IC50 = 1.18 μM), being 10× more active than the parent, [(η5-Cp*)Ir(2-phenylpyridine)Cl], and 2× more active than [(η5-CpxPh)Ir(2-phenylpyridine)Cl]. Intriguingly, contrasting biological activities are observed between structural isomers despite exhibiting similar chemical reactivity. For pairs of structural isomers both the nature and position of the functional group can affect the hydrophobicity of the complex. An increase in hydrophobicity resulted in enhanced cellular-iridium accumulation in A2780 ovarian cells, which generally gave rise to an increase in potency. The structural isomers [(η5-Cp*)Ir(2-(4′-fluorophenyl)pyridine)Cl] (2) and [(η5-Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] (4) preferentially localized in the cytosol > membrane and particulate > nucleus > cytoskeleton. This work highlights the strong dependence of biological behavior on the nature and position of the substituent on the chelating ligand and shows how this class of organometallic anticancer complexes can be fine-tuned to increase their potency without using extended cyclopentadienyl systems.